Data Sheet 1_Hyperbaric oxygen therapy for radiation enteritis and clinical parameters: a systematic review and meta-analysis.docx by Yuhan Wang (595964)

“…Moderate-quality evidence suggested that HBOT could significantly reduce the incidence of RE [OR = 0.32, 95% CI (0.14, 0.72), P = 0.006], particularly showing a significant advantage in decreasing the incidence of grade 3 or higher RE according to the RTOG/EORTC criteria [OR = 0.37, 95% CI (0.17, 0.82), P = 0.01]. …”

Data Sheet 1_Individualization of clinical target volume delineation in eccentric nasopharyngeal carcinoma: a prospective comparative study.docx by Yunrui Song (10672668)

“…</p>Results<p>Our results showed that compared with conventional CTV, the volume of CTV decreased significantly (P< 0.05) through individualizing delineation for eccentric NPC, especially CTV1 volume (95.81 cm³ vs. 57.57 cm³, P < 0.001). …”

Table 1_Real-world first-line serplulimab therapy for advanced esophageal cancer: effectiveness, safety, and clinical implications.docx by Fei Yan (128878)

“…Objective<p>The phase III ASTRUM-007 trial demonstrated significant clinical benefit in patients with PD-L1-positive esophageal squamous cell carcinoma (ESCC) treated with first-line serplulimab plus chemotherapy. …”

Data Sheet 1_Overexpression of KPC contributes to ceftazidime-avibactam heteroresistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae.docx by Yitan Li (1449217)

“…Silencing bla_KPC expression significantly decreased the CZA MIC in resistant subpopulations with high bla_KPC expression and hindered the emergence of CZA heteroresistance in their parental strains. …”

Image 1_Clinical study of PLA2R epitope spreading for predicting proteinuria remission in primary membranous nephropathy.pdf by Xueyang Cheng (22473883)

“…In the RTX group, epitope spreading significantly decreased at M6 (P = 0.004), and four patients (22.2%) with no clinical remission were ARA-positive. …”

Supplementary file 3_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Supplementary file 2_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Supplementary file 6_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Supplementary file 1_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Supplementary file 5_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Supplementary file 4_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

“…Objective<p>This study aims to develop a clinically applicable aerobic exercise prescription for children with asthma using a two-round Delphi consensus process and to preliminarily evaluate its feasibility and safety of this prescription in a pre–post pilot study. …”

Data analysed during this study. by Jakkrit Juhong (20968015)

“…In contrast, beta diversity analysis, assessed through Bray-Curtis dissimilarity, revealed significant differences in microbial composition between pre- and post-treatment samples. …”

Dataset for Generative artificial intelligence models in clinical infectiousdisease consultations: a cross-sectional analysis among specialists andresident trainees by Kwan Yeung Edwin Chiu (20718422)

“…Specialists consistently rated the responses more favorably than resident trainees, highlighting a discrepancy in clinical judgment. Cost analysis revealed decreasing operating expenses over time, but model performance was not directly correlated with cost. …”

Image 1_Yacon root is a functional food beneficial for human health: a meta-analysis of clinical trials.pdf by Ling-Hui Pan (9341084)

“…The pooled results showed that YR significantly reduced BMI [SMD = −0.81, 95%CI (−1.54, −0.08)], decreased stool pH [SMD = −1.12, 95%CI (−1.61, −0.62)], softened stools [SMD = 0.94, 95%CI (0.08, 1.80)], facilitated defecation [SMD = 4.03, 95% CI (0.54, 7.52)], improved fiber consumption patterns [SMD = 0.58, 95%CI (0.18, −0.99)]. …”

Adverse event list. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”

Patient characteristics. by Stefan Halbherr (21353882)

“…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …”

Table 1_Preliminary clinical activity of TP-0903 in relapsed or refractory acute myeloid leukemia with FLT3-ITD mutations.docx by Bhavana Bhatnagar (11016429)

“…All patients achieved stable disease; however, a significant reduction in bone marrow blast percentage after one to two cycles of treatment was observed in two patients, which correlated with a decrease in FLT3-ITD allelic ratio and variant allele frequency of co-occurring mutations (e.g., NPM1 and DNMT3A). …”

Image1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.tif by Xiaozhen Huang (5858690)

“…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”

Presentation 1_Identification and validation of lactate-related gene signatures in endometriosis for clinical evaluation and immune characterization by WGCNA and machine learning.p... by Jixin Li (5801207)

“…The objective of this research is to explore the clinical value and immune features of lactate-related genes in endometriosis and contribute novel strategies for guiding the clinical management of patients with endometriosis.…”

Table1_The clinical and genetic aspects of six individuals with GH1 variants and isolated growth hormone deficiency type II.docx by Xiaozhen Huang (5858690)

“…Background<p>Isolated growth hormone deficiency type II (IGHD II) is an autosomal dominant disorder characterized by a GH1 gene variant resulting in a significant reduction in growth hormone (GH) secretion and a subsequent decrease of plasma insulin-like growth factor 1 (IGF-1) levels and eventual growth impairment.…”